American Thoracic Society - Sanofi Investor Call
DupixentⓇ: Best-in-class execution in COPD
sanofi
2014 2015-2016-2017-2018-2019-2020-2021 2022 2023 2024 2025
DUPIXENT
(dupilumab)
Mepolizumab
METREX/METREO
18/20%1
BOREAS
30%¹
Triple therapy, >=300 cells/μL (screening), NO asthma history
MATINEE
Triple therapy, >=300/hist. >= 150 cells/μL (screening), asthma history
Benralizumab
GALATHEA/TERRANOVA
17/7%¹
RESOLUTE
NOTUS
Double/triple therapy, >=220 cells/μL (HEOS baseline), asthma history
1. Reduction in annualized rate in exacerbation vs. placebo
DupixentⓇ is under investigation in COPD and not yet approved by any regulatory agency to treat this indication. HEOS: High peripheral blood eosinophils (cutoff in cells/μL noted)
13 ATS Investor Call
Pivotal program resulting in
outstanding performance
园
BOREAS recruited as
many as 500 patients
during COVID pandemic
Highly significant and
clinically meaningful
improvement
in exacerbations, lung
function, quality of life,
and symptoms
(2) NOTUS recruitment
completed and on
track for readout in
2024View entire presentation